A rapid-acting antidepressant is a type of antidepressant medication which improves symptoms of depression quickly, within minutes to hours. In contrast to rapid-acting antidepressants, conventional antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), require weeks for their antidepressant effects to manifest.
Maps, Directions, and Place Reviews
History
Euphoriants like amphetamines and opioids produce rapid-acting antidepressant-like effects and were formerly used in the treatment of depression in the early 20th century. However, unlike the case of drugs like conventional antidepressants and ketamine, the antidepressant effects of euphoriants quickly disappear with chronic administration due to tachyphylaxis. Moreover, these drugs show long-lasting depressive effects with long-term use. Benzodiazepines have also presented a potential as a rapid strategy as an antidepressant although worsening moods has also been reported. In the year 2000, it is found that subanesthetic doses of the drug ketamine reduces depressive symptoms within 4 hours of administration in patients with severely treatment-resistant symptoms.
Fast Acting Depression Medication Video
Ketamine
The antidepressant effects of ketamine emerge as a reaction to the acute symptoms of ketamine being metabolized. Ketamine acts as an antagonist of the glutamatergic NMDA receptors, which rapidly increases presynaptic glutamate release while enhancing regional activity in excitatory networks, eventually changing synaptic plasticity and connectivity in the neurons. A low dose of ketamine administration initiates three rapidly consecutive events, a presynaptic disinhibition of glutamatergic neurons, leading to a glutamate surge, an increased activation of the AMPA glutamate receptor and a postsynaptic activation of neuroplasticity-related signaling pathways involving brain-derived neurotrophic factor (BDNF) and mechanistic target of rapamycin complex 1 (mTORC1), which results in overall synaptogenesis and synaptic potentiation. Further evidence in rodent studies given arketamine shows that AMPA activation is crucial for the antidepressant effects of ketamine.
Side effects
It has been shown that patients treated for depression with transmucal ketamine show no adverse side effects, though potential interactions with other drugs may cause adverse effects. Patients treated with ketamine intravenously show mild to moderate transient adverse effects including transient perceptual disturbances, dissociation, euphoria, dysphoria, and/or anxiety during infusion. When combined with drugs such as clonazepam, lorazepam, pregabalin, nortriptyline, hydroxyzine, doxepin and trazodone may cause CNS depression. Taking ketamine along with propranolol and doxazosin may cause hypotension, and combining ketamine with lisdexamfetamine and amphetamine/dextroamphetamine will lead to cardiovascular problems. Little is still known about the long-term safety and efficacy of repeated ketamine dosing, which appears to extend the benefits of single ketamine infusions.
Source of the article : Wikipedia
EmoticonEmoticon